

## Retraction Note

[NO AUTHORS LISTED]

The publisher and Editor in Chief have withdrawn four articles published between 2016 and 2018. These articles were discovered to contain problems, such as image manipulation, absence of ethics approval, and inconsistencies in data presented.

This retraction notice pertains to the following articles, with detailed explanations below:

- “The effects of MCA-MAO on cAMP pathway in rats with cerebral hemorrhage” by Y. Jiang, X.-F. Wang, Y.-L. Niu, J.-H. Xia-Eur Rev Med Pharmacol Sci 2016; 20 (9): 1834-1838-PMID: 27212177.

Readers have pointed out on PubPeer that Figures 1B and D appear to contain some overlaps. Moreover, there is no ethical approval statement for this study. The editorial team has contacted the authors but received no reply. The journal investigation revealed a figure duplication. Therefore, the Editor in Chief mistrusts the results and decided to retract the manuscript. Although the authors were notified of the retraction decision, they remained unresponsive.

- “Research on the role of GLP-2 in the central nervous system EPK signal transduction pathway of mice with vascular dementia” by C.-L. Chi, S.-A. Zhang, Z. Liu, M.-X. Chang, H. Wang, Y. Huang-Eur Rev Med Pharmacol Sci 2017; 21 (1): 131-137-PMID: 28121365.

Readers have pointed out on PubPeer that Figure 3 appears to contain some overlaps. Moreover, there is no ethical approval statement for this study. The editorial team has contacted the authors but received no reply. The journal investigation revealed a figure duplication. Therefore, the Editor in Chief mistrusts the results and decided to retract the manuscript. Although the authors were notified of the retraction decision, they remained unresponsive.

- “Studies on the relationship between P13K/AKT signal pathway-mediated MMP-9 gene and lung cancer” by H. Zheng, J.-F. Liu-Eur Rev Med Pharmacol Sci 2017; 21 (4): 753-759-PMID: 28272723.

Readers on PubPeer have expressed concerns about Western blots, as shown in Figure 2. Moreover, there is no ethical approval statement for this study. The editorial team has contacted the authors but received no reply. The journal investigation did not detect figure manipulation; however, since the lack of ethics statement and the lack of the original data, the Editor in Chief decided to retract the manuscript. Although the authors were notified of the retraction decision, they remained unresponsive.

- “LncRNA LINC01116 competes with miR-145 for the regulation of ESR1 expression in breast cancer” by H.-B. Hu, Q. Chen, S.-Q. Ding- Eur Rev Med Pharmacol Sci 2018; 22 (7): 1987-1993-DOI: 10.26355/eurrev\_201804\_14726-PMID: 29687853.

Readers on PubPeer have expressed concerns regarding inconsistencies between data presented in Tables and figures, deficiencies in the description of sample collection, and a lack of ethics approval. The editorial team has contacted the authors to request the raw data of the manuscript and a reply to those concerns but has not received any response. Throughout the journal investigation, numerous flaws and inconsistencies were discovered in the presented results. Therefore, the editors deem the conclusions of this article to be invalid and decided to retract the manuscript.

The corresponding author did not respond to journal correspondence about the investigation and retraction of this article.

These articles have been retracted. The Publisher apologizes for any inconvenience this may cause.